Mogamulizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CCR4 |
| Clinical data | |
| Trade names | Poteligeo |
| Routes of administration | IV |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6520H10072N1736O2020S42 |
| Molar mass | 146.44 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.[1]
Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.[2] It has also been licensed to Amgen for development as a therapy for Asthma.[3]
In 2016 it was in phase 1 clinical trials (in combination with utomilumab(PF-05082566)) for solid cancers.[4]
References
- ^ Subramaniam, J; Whiteside G; McKeage K; Croxtall J (18 June 2012). "Mogamulizumab: First Global Approval". Drugs. 72 (9): 1293–1298. doi:10.2165/11631090-000000000-00000. PMID 22686619. Retrieved 10 September 2012.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab" (PDF). American Medical Association.
- ^ "Kyowa Hakko Kirin R&D Pipeline" (PDF). Kyowa Hakko Kirin. Retrieved 10 September 2012.
- ^ A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |